Recent investigations have focused on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic neurotransmission. While GLP activators are widely employed for treating type 2 diabetes mellitus, their emerging consequences on reward circuits, specifically governed by dopamine syste